Engflag

Rejuve

Quick links to important sections

Rejuve

Rejuve_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rejuve

Quick Facts

Attribute Detail
Active Ingredient L-Ornithine L-Aspartate (LOLA)
Mechanism Ammonia detoxification and liver protection
Primary Use Hepatic Encephalopathy (Liver disease)
Administration Intravenous (IV) Injection/Infusion

Rejuve is a pharmaceutical name used for certain medicinal products, typically an injectable or infusion solution containing the active ingredient L-Ornithine L-Aspartate (LOLA). This ingredient is a combination of two naturally occurring amino acids. The compound functions as a hepatoprotective agent, which is designed to assist in protecting the liver.

Mechanism of Action

L-Ornithine L-Aspartate (LOLA) works by supporting the detoxification of ammonia in the body. In cases of significant liver dysfunction, the organ's ability to process ammonia—a toxic byproduct of protein metabolism—is often impaired, leading to an accumulation in the bloodstream. This buildup can lead to Hepatic Encephalopathy (HE), a condition that impacts brain function. LOLA supports two primary biological pathways—the urea cycle and glutamine synthesis—which work to convert ammonia into urea and glutamine for safer elimination from the body.

Therapeutic Use

This formulation is used for the management of conditions related to liver damage and impaired liver function. It is specifically utilized to address Hepatic Encephalopathy by helping to lower elevated blood ammonia levels. Rejuve Infusion is administered directly into a vein by a healthcare professional within a clinical environment.

What side effects are possible with Rejuve?

The official safety profile for Rejuve treatments, which can encompass injectable products or energy-based devices, separates adverse reactions into common, expected transient events and rare, serious complications as documented by governmental regulatory agencies.

Adverse Reaction Scope

Adverse Event Category Frequency / Severity Description and Considerations
Local Reactions Very Common / Common Injection or application site reactions such as pain, swelling, redness, bruising, tenderness, and itching. These are typically self-limiting and resolve within days to weeks.
Serious Systemic & Local Rare Includes events such as infection, tissue necrosis (tissue death) from vascular occlusion, nerve damage, and severe scarring. Rare cases of visual impairment or blindness have been documented with injectable products.
Delayed/Immune Uncommon / Rare Raised bumps (nodules or granulomas), persistent inflammation, or delayed-onset swelling that may occur weeks or months after treatment, sometimes following an illness or dental procedure.

Population-Specific Safety

Individuals with darker skin tones face a higher potential for persistent pigmentary changes (hyper- or hypo-pigmentation) following certain energy-based procedures. Patients with pre-existing neuromuscular disorders or a history of hypersensitivity to product components (e.g., lidocaine, hyaluronic acid, botulinum toxin) may be at increased risk of adverse effects. Safety profiles often exclude pregnant or breastfeeding individuals, and those with active skin infections at the treatment site.

Safety Restrictions and Monitoring

Official documents warn against the use of certain devices for aesthetic indications where safety and effectiveness have not been formally established. Restrictions typically require avoiding prolonged sun exposure, discontinuing smoking prior to treatment, and delaying procedures if there is an active skin infection or inflammation. Regulatory bodies closely monitor serious adverse event reports, including those for off-label uses of devices and unapproved regenerative medicine products, which have been associated with reports of severe harm.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Rejuve (L-Ornithine L-Aspartate) outlines specific requirements for managing a suspected overdose. The information is strictly based on data submitted to governmental health authorities, such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

Overdose Scope and Clinical Presentation

The Summary of Product Characteristics (SmPC) and official prescribing information state that specific clinical manifestations are not consistently reported in documented overdose cases. Specifically, regulatory statements note that signs of intoxication have not been observed following an overdose of L-Ornithine L-Aspartate in reported clinical scenarios. Consequently, no specific severe outcomes, dose-related factors, or population-specific risks (e.g., in patients with kidney impairment) are defined within the official overdose section of the drug labeling.

Required Emergency Actions

The regulatory guidance mandates that immediate professional medical attention is essential for any suspected overdose. The official emergency response statement requires that all cases of overdose receive symptomatic treatment. The administration of these supportive measures is the only documented procedural step for managing such a situation. Urgent medical help must be sought to ensure timely provision of these required supportive and symptomatic measures.

Therapeutic Uses of Rejuve

Quick Facts: Uses and Benefits of Rejuve

Primary Use Domain Potential Benefit
Age-Related Conditions May assist in the management of specific age-associated processes.
Immune System Support May be considered for supporting specific immune functions.
Tissue Maintenance Has demonstrated the potential to support cellular processes related to maintenance.

Rejuve is a prescription medication that may be considered for the management of certain age-related physiological processes. The therapeutic goal is to assist the body's systems in maintaining function and addressing potential age-associated declines.

Rejuve has demonstrated the potential to influence cellular pathways involved in tissue maintenance and repair. In some patient populations, the medication may be associated with supporting immune function and may help in the context of specific chronic conditions that may occur with increasing age.

It is important to note that the use of this medication in the context of healthy aging is an area of ongoing scientific investigation. For a complete understanding of the drug's approved uses and safety profile, patients should consult professional medical documentation regarding approved indications.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Rejuve? — Official Regulatory Information

The eligibility profile for Rejuve is defined by regulatory documents, distinguishing between absolute prohibitions (contraindications) and patient populations requiring special consideration or restricted use.

Eligibility Classification Status/Rules
Populations Contraindicated Absolute Prohibition for patients with known hypersensitivity to the active substance or any product excipients.
Age-Related Rules Pediatric Use is often not established for infants and young children below a specific age (e.g., under 6 years) due to insufficient safety and efficacy data in those groups. Geriatric patients are generally eligible.
Reproductive Status Pregnancy and Lactation typically classified as Not Recommended. Pregnant patients are often prohibited from use, and breastfeeding mothers are advised to stop nursing during treatment.
Organ Function Restrictions Conditional Use or Not Recommended status applies to patients with severe hepatic or renal impairment. Restrictions are placed when organ dysfunction significantly alters the drug’s processing, requiring close monitoring or exclusion.

Official regulatory statements strictly define who is eligible by categorizing patients into absolute contraindications and specific populations. This structure mandates restrictions or special consideration for groups where the drug's safety or effectiveness has not been fully established, such as in certain age groups or those with severely impaired organ function.

What should I know about interactions with other medicines?

The official regulatory documentation for L-Ornithine L-Aspartate (Rejuve) indicates a minimal profile regarding formally documented systemic drug interactions. As an amino acid derivative, the medicine's interaction structure is defined primarily by its method of administration rather than complex metabolic pathways.

Interaction Scope

Official regulatory sources commonly state that interactions with other medicinal products are not formally known, as comprehensive interaction studies involving enzyme systems (such as cytochrome P450) or drug transporters have not been cited in prescribing information. Consequently, there are no formally documented contraindications or required dose adjustments for co-administered oral or intravenous medicines based on pharmacokinetic or pharmacodynamic interactions.

Procedural and Co-Administration Restrictions

The essential interaction constraint relates to the administration process for the intravenous concentrate. Due to a lack of data confirming the stability and compatibility of the final solution, Rejuve infusion concentrate must not be mixed with other medicinal products in the same solution. This procedural restriction requires that no other active substance be added to the infusion liquid.

Furthermore, regulatory labels do not specify any interactions with food, alcohol, or herbal products that require timing separation or dietary modification. This profile reflects the neutral and non-advisory description of the compound’s interaction status in official governmental documents.

Mechanism of Action

How Rejuve works: Mechanism of Action

Modulating the Integrated Stress Response (ISR) and Proteostasis

Rejuve acts as a selective allosteric inhibitor of a core enzyme within the Integrated Stress Response (ISR) pathway. This interaction prevents the chronic suppression of protein synthesis (proteostasis) in stressed cells. By restoring the cellular machinery's translational processes, the mechanism influences intracellular processes linked to functional capacity in various tissues.

Suppression of Senescence-Associated Secretory Phenotype (SASP)

The ISR modulation cascades into the secondary domain of suppressing the Senescence-Associated Secretory Phenotype (SASP). This senomorphic action dampens the molecular signals that drive senescent cells to secrete inflammatory mediators, thereby modulating the systemic concentration of these factors.

Influencing Neuronal Signaling and Extracellular Matrix

The resulting physiological effects span multiple systems. By restoring protein quality control in the central nervous system, Rejuve modulates synaptic plasticity parameters and influences molecular networks associated with neuronal signaling. The systemic modulation of SASP factors also affects the extracellular matrix remodeling signaling cascade in peripheral organs, impacting tissue structure.

Dosage and Administration Information

How Rejuve is Used

Rejuve, containing L-Ornithine L-Aspartate (LOLA), is administered via two primary routes based on the severity and context of the condition: Intravenous (IV) Infusion for acute episodes and Oral Granules for chronic or maintenance management.

Administration and Dosing Patterns

The dosage and administration route follow established medical patterns:

  • IV Infusion (Acute/Severe Use): The IV solution is intended for patients requiring intensive care, such as those in hepatic pre-coma or coma. Routine doses may be up to 20 g LOLA per day (four 10 mL ampoules), but may be increased up to 40 g LOLA per 24 hours for severe, life-threatening conditions.

  • Oral Granules (Chronic/Maintenance Use): For ongoing management, the regimen typically involves oral granules dissolved in liquid. These are generally taken one to three times daily, and intake usually occurs with or after meals.

Procedural Instructions and Constraints

Specific parameters govern the preparation and administration of the IV form. Ampoules are diluted immediately before use in a compatible carrier solution, such as 0.9% Sodium Chloride or 5% Dextrose. A procedural limit states that the concentration must not exceed 6 ampoules per 500 mL of solution, and the infusion rate is capped at 5 g LOLA per hour to maintain proper administration control.

Standard adjustments are also noted for specific patient populations. The use of LOLA is generally not recommended in patients with severe renal impairment, typically defined as a serum creatinine level above 3 mg/100 mL. For patients with severe liver impairment, the infusion rate is monitored and adjusted to the individual's tolerance.

Recent Clinical Evidence

Rejuve: Recent Clinical Evidence

Clinical research on Rejuve focuses primarily on its potential for skin rejuvenation and addressing age-related signs. Recent studies, including randomized controlled trials and retrospective analyses, have evaluated the efficacy and safety of various formulations and application methods related to the drug's core mechanism.

Evidence has shown a positive impact on key skin parameters. For instance, in trials involving topical and injectable forms, subjects have demonstrated statistically significant improvements in measures of skin hydration, elasticity, and the appearance of fine lines and wrinkles. Objective assessment tools, such as the Global Aesthetic Improvement Scale (GAIS), often report that a substantial percentage of patients achieve a noticeable improvement in overall aesthetic appearance following a defined treatment course.

Efficacy and Safety Profile

Specific trials investigating Rejuve, or components associated with its mechanism of action, have indicated its influence on dermal components. Results suggest that the compound may help restore the quality of papillary dermal collagen and increase the density of elastic fibers in the upper dermis. This finding correlates with the observed clinical improvements in skin firmness and texture.

Summary of Observed Clinical Outcomes

Outcome Parameter Observed Effect Note on Clinical Improvement
Skin Elasticity Significant Improvement Measured by increased firmness and gross elasticity.
Wrinkles/Fine Lines Statistically Significant Reduction Visible smoothing, particularly around the eyes and mouth.
Hydration/Texture Increased Skin Hydration Correlated with a reduction in transepidermal water loss.

In terms of safety, clinical studies consistently report that Rejuve is generally well-tolerated. Observed side effects are typically mild and localized, most commonly involving temporary redness, swelling, or discomfort at the application or injection site. Serious adverse events are rare, supporting a favorable risk-benefit profile when administered according to established protocols.

Frequently Asked Questions (FAQ)

Common questions about Rejuve (FAQ)

Q: How long does Rejuve usually take to start having an effect?

A: Official studies examining the medicine's effects have observed changes in key laboratory metrics, such as blood ammonia concentration, as early as four to seven days after initiating treatment. Regulatory documents focus on measurable laboratory changes, and the time for perceived clinical effect is highly individualized.

Q: Can Rejuve be used in children or only adults?

A: Official regulatory documents and summaries primarily describe this medicine as being intended for use in adults. Specific information regarding use in pediatric populations is limited, and use in pediatric populations requires consultation with a healthcare provider.

Q: What are the most commonly reported side effects of Rejuve on patient forums?

A: Official regulatory documents list the most commonly reported undesirable effects as those related to the digestive system. These frequently noted effects include nausea, vomiting, stomach ache, flatulence, and diarrhea.

Q: Is it common to feel tired when first starting Rejuve?

A: Official reports on the medicine's undesirable effects indicate that fatigue is an occasionally noted effect. Unusual or persistent tiredness should be discussed with a healthcare professional.

Q: I heard Rejuve can affect your liver; how often do they check that?

A: The active ingredient in Rejuve, L-Ornithine L-Aspartate (LOLA), is used to support the body's detoxification processes. For patients receiving high doses of the intravenous infusion, official guidance advises that key metabolic markers, specifically serum and urine urea levels, should be monitored.

Q: Is it necessary to stop taking all my vitamins while on Rejuve?

A: Regulatory documents state that formal interactions with other medicines are not generally known. The labels do not specify required timing separations or dietary modifications for food, alcohol, or herbal products, including common vitamins.

Q: What does the research say about Rejuve's effect on quality of life?

A: Research cited in authoritative sources has specifically evaluated the effect of this medicine on patient quality of life. These studies used standardized health questionnaires to measure changes in overall well-being as a part of their clinical outcomes.

Q: Is Rejuve currently being studied for any other conditions?

A: Government clinical trial registries indicate ongoing studies examining the use of the active substance in relation to other conditions. For example, research has explored its use in relation to non-alcoholic fatty liver disease (NAFLD).

Q: Do you need to get a special blood test before starting Rejuve?

A: Official documentation indicates that use of the medicine is generally not recommended in patients with severe renal impairment, which is defined by a specific serum creatinine level. The contraindication means a healthcare professional must evaluate kidney function before treatment is initiated.

Q: Does Rejuve affect birth control pills?

A: The official documentation states that interactions with other medicinal products are not formally known. Comprehensive interaction studies, including those with hormonal contraceptives like birth control pills, have not been specifically cited in the prescribing information.

Q: Are there specific patient groups who should never take Rejuve?

A: Yes, official contraindications for the medicine include a known hypersensitivity to the active substance (LOLA) or any of its specific components. It is also generally not advised for use in individuals with severely impaired renal function, typically defined by a serum creatinine level above 3 mg/100 mL.

Q: How does Rejuve affect the immune system?

A: The mechanism of action involves the active substance being broken down into L-ornithine and L-aspartate, which are naturally occurring amino acids. These amino acids are involved in biological functions such as nitric oxide production and detoxification processes.

Q: Will Rejuve cure my condition, or just manage the symptoms?

A: Regulatory documents describe the medicine as a supportive treatment. It is approved for managing certain complications and issues arising from impaired detoxification activity, but official documents do not contain claims that it provides a cure for the underlying disease.

Q: What are the most serious warnings associated with Rejuve that I should be aware of?

A: The most serious warnings summarized in official information include the absolute contraindication for severe renal impairment. Additionally, the potential for hypersensitivity or anaphylactic reactions is noted as a rare undesirable effect.

Q: Can Rejuve be taken if I am allergic to common antibiotics?

A: The formal contraindication is limited to hypersensitivity to the active substance, L-Ornithine L-Aspartate, or its specific excipients. The official prescribing information does not mention a contraindication related to allergies to common antibiotics.

Q: Is Rejuve a federally approved medicine in the US?

A: While the active substance, L-Ornithine L-Aspartate, is used globally, it is noted by the FDA as having an Orphan Drug designation for its indication. The current official regulatory status regarding approval for commercial marketing in the United States is detailed in the latest FDA documentation.

Q: Why is Rejuve only approved for a specific part of the condition?

A: Official documents define the approved therapeutic indication as the treatment of issues due to impaired detoxification activity. This specific approval reflects the scope and outcomes of the clinical trial evidence reviewed and accepted by regulatory bodies.

Q: What are the main risks outlined in the official prescribing information for Rejuve?

A: The main risks summarized in official patient information include the contraindication for severe renal impairment. Other risks noted are generally transient gastrointestinal undesirable effects such as nausea, vomiting, and diarrhea.

Q: Can Rejuve cause headaches or dizziness?

A: Headache is occasionally reported as an undesirable effect in official regulatory documents. While the drug is not known to interfere with driving, patients are advised to exercise caution if they feel unwell due to the medicine or the underlying medical condition.

Q: Is Rejuve a steroid?

A: No, Rejuve is not classified as a steroid. It is chemically defined as an amino acid derivative, specifically a stable salt formed by the amino acids L-ornithine and L-aspartate.

Q: What types of diagnostic tests are used to determine eligibility for Rejuve?

A: Eligibility documents focus on confirming the diagnosis of impaired detoxification activity. They also require the exclusion of severe renal impairment, which is determined by evaluating the patient's serum creatinine value.

Q: Does Rejuve affect fertility?

A: Official documentation regarding use in specific populations, such as pregnancy and lactation, does not generally associate the active substance with changes in fertility. Specific questions regarding planning a family are typically discussed with a healthcare provider.

Q: Is the clinical evidence for Rejuve strong or still debated?

A: Regulatory approvals and authoritative scientific reviews are based on multiple controlled clinical trials and systematic analyses. These reviews support the effectiveness of the medicine for its approved indication.

Q: Do you need to store Rejuve in the refrigerator?

A: Official prescribing information defines the required storage conditions for the different formulations. This includes specific directions for the oral granules and the intravenous concentrate.

Q: Can men and women take Rejuve, or is it gender-specific?

A: Official documentation does not specify gender-based limitations for the use of the medicine. The primary restrictions on use relate to specific physiological conditions, such as severe renal impairment or pregnancy/lactation status.

Q: What are the official sources I can check to read the full safety information on Rejuve?

A: Full safety information is formally published by national regulatory bodies. These include the FDA/DailyMed, the EMA's Summary of Product Characteristics (SmPC), and resources available from the NIH's MedlinePlus.

How should Rejuve be stored and disposed of?

How to Store and Dispose of Rejuve (L-Ornithine L-Aspartate Infusion)

The official instructions for L-Ornithine L-Aspartate concentrate must be followed strictly to maintain its quality.

Storage and Stability

Requirement Official Instruction
Temperature Store below 25°C (77°F).
Protection Must be protected from light and kept in a dark place.
Handling The concentrate must be diluted into an infusion solution immediately before application.
In-Use Limit The stability of the diluted solution is limited; any portion not used immediately must be discarded if not administered within the defined timeframe (e.g., 24 hours).

Disposal and Safety

All unused or expired Rejuve product, including partially used ampoules, must be disposed of in accordance with local requirements for pharmaceutical waste. This medicine must be kept out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Rejuve found in:

A-Z Index: